Ichnos Pharmaceuticals

Ichnos Sciences is a private, clinical-stage biotechnology company focused on oncology and immunology, historically operating as Glenmark Pharmaceuticals' innovation-focused biotech subsidiary. In 2024, Ichnos and Glenmark formed the Ichnos Glenmark Innovation alliance to advance a pipeline of multispecific biologics and selected small molecules, with a particular emphasis on cancer therapeutics. Its lead asset is ISB 2001, a CD38 + B-cell maturation antigen (BCMA) + CD3 trispecific antibody in Phase 1 for relapsed/refractory multiple myeloma and later partnered with AbbVie in licensed territories. The company is best known for its BEAT multispecific antibody platform, used to generate bispecific and trispecific immune-cell-engaging biologics. Its broader portfolio has included OX40-targeting immunology antibodies, an Interleukin-1 receptor accessory protein-targeting antibody, and earlier-stage oncology assets for hematologic malignancies and solid tumors.